Oxford MEStar will be attending the MEDICA trade fair in Düsseldorf (November 18th-21st 2019) as part of the ABHI UK pavillion in Hall 16 (stand 16K03-3) and announcing the launch of their new product - measurePRO.
Measure Bowel Health, the worlds first digital faecal occult blood (FOB) testing device, provides a fast, hygienic way of detecting signs of bowel cancer early. The device uses patented technology to detect signs of bowel cancer, producing a fast, easy-to-read result for the user.
Oxford MEStars CEO Dr Robert Wang explains: “The Measure bowel cancer test is the first in a line of digital testing kits that we are currently developing in support of early stage screening.”
Measure Bowel Health was launched as an at-home, self-testing kit in the UK in April 2018, a new version of the product, aimed at the primary care market, will be announced at MEDICA 2019. MeasurePRO will see new changes to the original design while employing the same sensor technology as Measure, helping to produce results that the company describe as faster and more hygienic when compared to other tests.
MeasurePRO, which will be launched later this year, is a point-of-care device that operates with the same easy-to-use technology as Measure. The professional testing kit, designed for the primary care market, comes with changes to the design, including:
A multi-use reader with a rechargeable battery and data connectivity.
A new cartridge design that allows users to take stool samples at home and seal them into the cartridge for transport. The professional user then initiates the test in their clinic/GP office.
Dr Wang concludes “Supporting early diagnosis in bowel cancer is vital. We look forward to launching our professional testing kit at MEDICA as well as expanding our distribution of the self-test product in other EU countries and beyond.”
About Oxford MEStar
Founded in 2013, Oxford MEStar Ltd is a spin-out of the Institute of Biomedical Engineering at the University of Oxford. As well as new digital health diagnostics technologies, the company is developing automated bioreactors for cell therapy manufacturing and tissue engineering.